Research programme: epcitabine prodrugs - Idenix
Alternative Names: L-dC prodrugs - IdenixLatest Information Update: 04 Apr 2007
At a glance
- Originator CNRS; Idenix Pharmaceuticals; University of Alabama at Birmingham
- Class
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 23 May 2006 No development reported - Preclinical for Hepatitis B in France (PO)
- 23 May 2006 No development reported - Preclinical for Hepatitis B in USA (PO)
- 09 May 2003 Novartis Pharma AG has acquired a majority equity interest in Idenix